NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Telomir Pharmaceuticals, Inc. (TELO) Stock Analysis

Telomir Pharmaceuticals, Inc. (TELO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TELO

$1.02

+$0.01 (+0.99%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TELO with… →

TELO Key Statistics

As of Oct 21, 2026
Trading
Open
$1.01
Previous Close
$1.01
Day's Range
1.01–1.06
52-Week Range
0.89–1.58
Volume
37.66K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.30
Valuation
Market Cap
$75.09M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.11
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$10.41M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
73.62M
1-Year Return
−32.00%
Dividend and dates
Avg Volume
89.38K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TELO closed at $1.02, −32.00% over 1 year.

Telomir Pharmaceuticals, Inc. (TELO) has a market capitalization of $75.09M.

In fiscal 2025, TELO reported revenue of $0.00.

TELO Stock Return by Calendar Year

Telomir Pharmaceuticals, Inc. (TELO) return since Feb 2024: what $10,000 became

1 year
$10,000 $6,800
−32.00%
Since Feb 2024
$10,000 $2,040
−79.60%

If you had invested $10,000 in Telomir Pharmaceuticals, Inc. (TELO) at the close on February 9, 2024, the earliest close on record here, it would have been worth $2,040 at the close on October 21, 2026: −79.60% in total, −44.54% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−23.31%
2025−67.72%
2024 (partial year)−17.60%

As of October 21, 2026.

TELO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$10.41M—
2024$0.00−$16.53M—
2023$0.00−$13.07M—
2022$0.00−$854.15K—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$10.54M−$10.41M—
2024$0.00—−$12.24M−$16.53M—
2023$0.00—−$3.94M−$13.07M—
2022$0.00—−$854.15K−$854.15K—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Telomir Pharmaceuticals, Inc. (TELO) at $75.09M. It is classified in the Biotechnology industry, within the Healthcare sector.

The most recent close on file for TELO is $1.02, dated October 21, 2026. That is +$0.01 (+0.99%) against the previous close. Over the past 52 weeks the price has ranged from $0.89 to $1.58. The latest close sits 14.86% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $10.41M. Earnings per share on a trailing basis come to −1.11.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −32.00%. The stored price history starts on February 9, 2024, and the total return since then is −79.60%. Beta against the wider market is reported at −0.3. Annualized volatility over the trailing 2 years is 106.55%.

Growth & Income

The record shows no dividend for TELO.

The record holds one complete calendar year, 2025, which returned −67.72%. So far in 2026 the total return is −23.31%.

Peer Comparison

Telomir Pharmaceuticals, Inc. (TELO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Telomir Pharmaceuticals, Inc. TELO $75.09M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Telomir Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

Visit website →